Zinc oxide sunscreens may interfere with copper peptide function
Preclinical research in mice has shown reductions in heart muscle mass and overall heart size after exposure to semaglutide
However, secondary factors like hypoglycemia, dehydration, gastrointestinal side effects, and vascular changes can trigger headaches
Employers can stay ahead of the GLP-1 curve by proactively evaluating coverage strategies and vendors, monitoring utilization trends, and leveraging data-driven insights to manage costs effectively in 2025 and beyond.
Wegovy (semaglutide) Injector 1.7 mg/0.75 mL, 4 Pens Per Box is a medication used for chronic weight management in adults with obesity or excess weight who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It is used in combination with a reduced calorie diet and increased physical activity. Wegovy is a glucagon-like peptide-1 (GLP-1) receptor antagonist and works by slowing down digestion, decreasing appetite, and increasing feelings of fullness, which helps with weight loss. It is administered as a subcutaneous injection and comes in a package of 4 pens for 4 weeks of treatment